麻豆传媒

haun William Davies is an Associate Professor of Finance and the Research Director of the Burridge Center for Finance at the Leeds School of Business at the University of Colorado at Boulder. Dr. Davies earned his Ph.D. at UCLA Anderson's Graduate School of Management in 2013, his M.A. in Economics at UCLA in 2010, and both his B.S. in Applied Mathematics and B.A. in Economics at the University of Colorado in 2005. Dr. Davies is also a CFA charterholder. Dr. Davies’ research interests are in Asset Management, Exchange-Traded Funds (ETFs), Target-Date Funds (TDFs), Socially Responsible Investing (SRI), Crowdfunding and Applied Game Theory. His research has appeared in leading peer-reviewed journals, including the Journal of Finance, Journal of Financial Economics, Review of Financial Studies, Review of Finance, Review of Asset Pricing Studies and Journal of Financial and Quantitative Analysis. Furthermore, his research has been featured in several media outlets including the Wall Street Journal, the Financial Times, and Bloomberg.
Dr. Davies teaches both undergraduate and MBA courses and is an award winning teacher and researcher; Dr. Davies was the recipient of the , Dr. Davies was the 2021-2022 , and Dr. Davies is a Daniels Fund Faculty Fellow. 

Asaf Bernstein is an associate professor of finance at the University of Colorado at Boulder's Leeds School of Business and a Faculty Research Fellow in the National Bureau of Economic Research. For 2021-2022 he will be serving as a Senior Advisor for Climate Issues for the Securities and Exchange Commission (SEC). Prior to joining Leeds he completed his PhD in Financial Economics at the Massachusetts Institute of Technology in 2016. His interests generally lie at the intersection of policy and finance, with a focus on "Mostly Harmless Macroprudential Policy" (financial policies supported by plausibly well-identified reduced-form empirics), and include work in economic history, household finance, real estate, corporate finance, and asset pricing.
Professor Bernstein's research has looked at the effect of financial regulations and institutions, including the Federal Reserve, rating agencies, centralized clearing, and mortgage assistance programs. This work has been published in the Journal of Political Economy, Quarterly Journal of Economics, Journal of Finance, Journal of Financial Economics, Review of Financial Studies, and American Economic Journal: Economic Policy, and received numerous awards, including the 2019 AQR Insight Distinguished Paper Award. Based on his graduate work he received the 2016 AQR Top Finance Graduate Award by Copenhagen Business School, which recognizes the six most promising finance PhD graduates in the world. Prior to graduate school, he received his B.S. in Economics and Mathematics at Harvey Mudd College and worked as a quantitative trader at an investment bank in New York.

Doug Spencer is a Professor of Law at the University of Colorado. Professor Spencer is an election law scholar whose research addresses the role of prejudice and racial attitudes in voting rights litigation, the empirical implications of various campaign finance regulations, and the ways that election rules and political campaigns contribute to growing inequality in America.
 
Before moving to Colorado, Professor Spencer was Professor of Law & Public Policy at the University of Connecticut from 2013-2021. He has also taught as a Visiting Professor at the Yale Law School (2020) and the University of Chicago Harris School of Public Policy (2018-2019). His research has been published or is forthcoming in the California Law Review, Columbia Law Review, Cornell Law Review, Indiana Law Journal, Iowa Law Review, Northwestern Law Review, University of Illinois Law Review, Yale Law & Policy Review, Yale Law Journal Forum, Journal of Law & Courts, and the Election Law Journal. His work has also been featured in The New York Times, Wall Street Journal, Slate and other media outlets.
 
Professor Spencer has worked as an expert witness in voting rights and campaign finance cases and, prior to law teaching, was a law clerk at the Lawyers' Committee for Civil Rights in San Francisco, an election monitor in Thailand for the Asian Network for Free Elections, and a researcher for the Pew Center on the States' Military and Overseas Voting Reform Project.
 
Professor Spencer holds a Ph.D. in Jurisprudence and Social Policy from the University of California, Berkeley. He also earned a J.D. at Berkeley Law and a M.P.P. at the Goldman School of Public Policy at UC Berkeley. He graduated magna cum laude from Columbia University in 2004 with a B.A. in Philosophy.

Professor P. (Deep) Gulasekaram teaches Constitutional Law and Immigration Law. His research focuses on the constitutional rights of noncitizens and federalism concerns in immigration law.

He is co-author of the leading immigration law casebook used in law schools (Immigration & Citizenship: Process and Policy (West Academic 9th Ed. 2021)). His book, The New Immigration Federalism, provides an in-depth empirical and theoretical analysis of the resurgence of state and local immigration lawmaking. He has also extensively explored the relationship between the Second Amendment and immigrants, as a way of understanding constitutional protections for noncitizens. In addition to his scholarly publications, Professor Gulasekaram frequently comments on constitutional and immigration developments for national media outlets, and contributes pieces for the L.A. Times, the Washington Post, and SCOTUSblog, among other outlets.

Prior to Colorado Law, he was Professor of Law at Santa Clara University and taught as Visiting Professor at Stanford Law School, Berkeley Law School, University of California Berkeley, and as Acting Assistant Professor of Lawyering at New York University School of Law. Prior to academia, he was a litigation associate with O'Melveny & Meyers LLP and Susman Godfrey LLP, both in Los Angeles. He clerked for the Honorable Jacques L. Wiener Jr. on the U.S. Circuit Court of Appeals for the Fifth Circuit in New Orleans. In addition, he is the co-founder of the , a non-profit organization dedicated to improving health and educational infrastructure for children in developing areas around the world.

Vivek Krishnamurthy is an Associate Professor of Law and Director of the Samuelson-Glushko Technology Law and Policy Clinic (TLPC) at the University of Colorado Law School.

Vivek's teaching, scholarship, and clinical legal practice focus on the complex regulatory and human rights-related challenges that arise in cyberspace. He advises governments, activists, and companies on the human rights impacts of new technologies and is a frequent public commentator on emerging technology and public policy issues.

Vivek was previously the Samuelson-Glushko Professor of Law at the University of Ottawa, where he served as the director of CIPPIC--the Samuelson-Glushko Canadian Internet Policy and Public Interest Clinic. He is a Rhodes Scholar and clerked for the Hon. Morris J. Fish of the Supreme Court of Canada upon his graduation from Yale Law School. Vivek is currently a Faculty Associate of the Berkman Klein Center for Internet & Society at Harvard University, a Senior Associate of the Human Rights Initiative at the Center for Strategic and International Studies, an Associate Member of the Centre for Law, Technology and Society at the University of Ottawa, and an alternate member of the Global Network Initiative's Board of Directors.

Dr. Lieping Chen is an immunologist interested in basic T cell biology, cancer immunology, and translational research to develop new treatments for human diseases including cancer. Prior to joining Yale, he was a faculty member at Johns Hopkins University School of Medicine and Mayo Clinic, and a scientist in Bristol-Myers Squibb Pharmaceutical Research Institute.
Dr. Chen has published over 370 peer-reviewed research articles. His work in the discovery of the PD-1/PD-L1 pathway for cancer immunotherapy was cited as the #1 breakthrough of the year by Science magazine in 2013. He is a member of the National Academy of Sciences and a fellow of the American Association for Cancer Research and the Society for Immunotherapy of Cancer.

Kiran Turaga, MD, MPH, is Division Chief of Surgical Oncology in the Department of Surgery and Assistant Medical Director for the Clinical Trials Office at Yale Cancer Center. Dr. Turaga joined Yale Cancer Center and Smilow Cancer Hospital from the University of Chicago where he was Vice Chief of the Section of General Surgery and Surgical Oncology, Director of the Surgical Gastrointestinal Cancer Program, and Director of Regional Therapeutics.
Widely considered a thought leader in the management of oligometastatic cancer, Dr. Turaga is an expert in regional perfusion including hyperthermic intraperitoneal chemotherapy (HIPEC), a technique that delivers high doses of heated chemotherapy directly to abdominal organs to kill cancer cells that may remain after surgical removal of visible tumors. His research focuses on development of novel diagnostics and therapeutics for oligometastatic cancer and is currently the principal investigator on several clinical trials exploring the interface of immunotherapy and liquid biopsy in the surgical management of cancer. He is also interested in studying how big data systems can be used to provide the most optimal, cost-effective patient care.

My clinical and research interests are in the diagnosis and treatment of breast cancer. I am interested in clinical trial development and investigation of novel or new treatment options for patients with breast cancer. I am also interested in improving access to clinical trials to diverse patient populations. 






Education

Residency, INTERNAL MEDICINE - Boston University, School of Medicine
M.D. 2016 - Boston University, School of Medicine




 
I am interested in clinical research to develop novel therapeutic agents to further advance the field of breast oncology. My goal is to further the development of novel therapeutic agents through clinical trial development and better access to clinical trials for all patients. I've been involved in research projects to improve the care oncology patients receive as well as clinical research to investigate the genomic differences within breast cancer and how we can find targets to continue to improve personalized breast cancer treatment.





 

I specialize in the treatment of gastrointestinal (GI) cancers with a focus on clinical trials. Clinical trial patients can come to me at any point during their disease, but they usually come to me looking for an alternative therapy once standard treatments have not been effective. I decided to become a doctor later in my career. I originally graduated from university with a non-science degree, but the excitement of advancing medical breakthroughs inspired me to start a career in medicine. As a Duke physician, I enjoy the diverse experiences that I get to have each week. In addition to taking care of patients and conducting research, I work closely with other doctors on crafting treatment plans. I also find it fulfilling to be able to apply my research to patient care. In my spare time, I enjoy spending time with my family, jogging and skiing.
Education

Fellowship in Hematology-Oncology, MEDICINE - Duke University, School of Medicine
Residency, MEDICINE - University of Washington
M.D. 2005 - The University of Chicago

 is a professor of psychology at the University of Illinois Urbana-Champaign and a researcher at the Beckman Institute for Advanced Science and Technology.
As an experimental psychologist, Professor Kurdi’s research seeks to understand the immense power and the surprising limitations of our minds in adaptively responding to new information given a lifetime of learning. He examines learning in the context of basic social processes. Specifically, he studies the ordinary decisions we make every day that are critical to our well-being and even survival: our evaluations of and beliefs about other people. In doing so, he relies on a combination of traditional online and laboratory experiments as well as computational approaches, while drawing on a variety of learning paradigms, including reinforcement learning, evaluative conditioning, propositional learning, and causal learning. These methods help him uncover the basic mechanisms involved in how we acquire and update our impressions of individuals, especially against the backdrop of information about their social group memberships, such as gender, sexual orientation, age, race, and ethnicity.
Research Areas:


Social Personality


Research Interests:


Implicit Attitude Change


Attitudes in the Wild


Computational Approaches


Open Science and Resources


Education


B.A., Eotvos Lorand University, 2011


M.A., political science, Central European University, 2013


M.A., psychology, Harvard University, 2019


Ph.D., psychology, Harvard University, 2019

Academic Director, Mohs and Dermatologic Surgery CenterDirector, High-Risk Skin Cancer Clinic, Dana-Farber Brigham Cancer Center Director, Micrographic Surgery and Dermatologic Oncology Fellowship Program
Associate Professor of Dermatology, Harvard Medical School







Leadership Title

Academic Director, Mohs and Dermatologic Surgery Center
Director, High-Risk Skin Cancer Clinic, Dana-Farber Brigham Cancer Center
Program Director, Micrographic Surgery and Dermatologic Oncology Fellowship Program


 

Specialties
Dermatology



Clinical Interests

Basal Cell Carcinoma
Cutaneous Oncology (Skin Cancer)
Dermatologic Oncology
Melanoma
Mohs Surgery
Non-Melanoma Skin Cancer
Public Health
Squamous Cell Carcinoma











 
Education





Internship
New York University Langone Medical Center, 2010 - 2011

 

Medical School
New York University School of Medicine, 2006 - 2010

 

Residency
Albert Einstein College of Medicine, 2011 - 2014



Board Certifications
Dermatology, 2014
Micrographic Dermatologic Surgery, 2021

Ann W. Silk is a medical oncologist at Dana-Farber Cancer Institute. Ann does research in Clinical Immunology and Oncology with a specialty in Merkel cell carcinoma and other non-melanoma skin cancers. Her research interests are intratumoral oncolytic viral therapy, IL-2 therapy, macrophage directed therapy, cancer vaccines, and brain metastases.

 






Physician

Co-Director of the Merkel Cell Carcinoma Center of Excellence
Physician
Assistant Professor of Medicine, Harvard Medical School
 



Centers/Programs














 
Diseases Treated


















 
Board Certification


Internal Medicine, 2011
Medical Oncology, 2014




 
Fellowship


University of Michigan Health System




 
Residency


University of Pittsburgh Medical Center




 
Medical School


University of Pittsburgh School of Medicine

Director, Mohs and Dermatologic Surgery Center Brigham and Women's Faulkner Hospital, Director, Mohs Surgery, VA Boston Healthcare System
Assistant Professor, Harvard Medical School
Dermatology

 







Leadership Title

Director, Mohs and Dermatologic Surgery Center
Director, Mohs Surgery, VA Boston Healthcare System


 

Specialties
Dermatology



Clinical Interests

Basal Cell Carcinoma
Cosmetic Dermatology
Cutaneous Oncology (Skin Cancer)
Laser And Cosmetic Surgery
Melanoma
Mohs Surgery
Non-Melanoma Skin Cancer
Squamous Cell Carcinoma












 
Education

Internship
Memorial Sloan Kettering Cancer Center, 2011 - 2012

 

Medical School
Yale University School of Medicine, 2006 - 2011

 

Residency
Yale New Haven Hospital, 2012 - 2015



Board Certifications
Dermatology, 2015
Micrographic Dermatologic Surgery, 2021



Fellowship
Northwestern University Feinberg School of Medicine, 2015 - 2016

Dr. Lakshmi Nayak serves as Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston. She is an Associate Professor of Neurology at Harvard Medical School. She received her medical degree at Grant Medical College in Mumbai, India. She completed her residency at New York Presbyterian Hospital/ Cornell, and fellowship at Memorial Sloan-Kettering Cancer Center in New York. Her research includes development of novel therapies through preclinical and clinical studies for management of primary brain tumors including glioblastoma and primary central nervous system lymphoma, with particular focus on molecular targeted agents and immunotherapeutics, including CAR T-cell therapy.  She leads the international neurologic assessment in neuro-oncology (NANO) effort for evaluation of neurologic function in patients with brain tumors. 

Dr. Partridge received her MD from Cornell University Medical College in 1995. She completed her residency in internal medicine at the Hospital of the University of Pennsylvania and went on to complete fellowships in medical oncology and hematology at DFCI, MGH and BWH. She also received an MPH from Harvard School of Public Health. She is a medical oncologist who cares for adults with breast cancer, with a particular focus on the unique needs of young patients with breast cancer.  She also leads efforts to optimize cancer survivorship care and research at DFCI.

Chunyuan Diao has been an assistant professor of Geography and Geographic Information Science at the university of Illinois Urbana-Champaign since 2017. She teaches courses including Introduction to Remote Sensing, Techniques of Remote Sensing, and Programming for GIS.
Her research focuses on computational remote sensing of terrestrial ecosystem dynamics at local to global spatial scales and daily to decadal temporal scales. She has a particular interest in advancing computational remote sensing paradigms in characterizing land surface patterns and processes, underlying mechanisms, and subsequent feedbacks to the atmosphere. Her work combines remote sensing, process-based models, field observations, artificial intelligence, and high-performance and cloud computing to study ecosystem structures, functions, and responses to climate change and human activities. This research traverses varying ecosystems, including natural (e.g., forest), human-dominated (e.g., agriculture), and disturbed (e.g., species invasion) ecosystems. Current focus areas include computational remote sensing, multi-scale land surface phenology, intelligent agriculture, and invasive species and biodiversity.
Her research team has developed a novel framework, called CropSight, to retrieve the object-based crop type ground truth. CropSight is a unique national-scale crop ground reference data repository and embodies a wealth of season-long remotely sensed crop growth and environmental attributes across crop growing locations for most crop types in the U.S.
She is a fellow of the Association of American Geographers and previously received the Early/Mid-Career Research Award from the University Consortium for Geographic Information Science (2023), a National Science Foundation CAREER Award (2021), the NASA Early Career Investigator Award (2021), and AAG Early Career Scholars in Remote Sensing Award (2020).
Research interests

Time series remote sensing, space-time analytics
Vegetation phenology, continuous vegetation monitoring
Computational remote sensing, deep learning
Agriculture, forest, and invasive species dynamics

Education

PhD, Geography, State University of New York at Buffalo
MA, Biostatistics, State University of New York at Buffalo
BS, Beijing Normal University

Website

Barbara Burtness, MD, is a Yale Medicine medical oncologist who sees patients at Yale Cancer Center. She has made it her life’s mission to help people diagnosed with head and neck cancer, which can be a devastating disease even after it is cured—it can impact a person’s appearance, as well as the ability to speak, swallow, and eat.
“Patients often encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration, and feeding tube dependence,” says Dr. Burtness. “Younger patients may have to deal with these side effects for decades after cancer treatment.”
A careful treatment approach can help prevent these problems. She and her team evaluate the tumor location and decide which primary treatment (surgery or radiation therapy) will best cure the cancer and cause the fewest possible negative outcomes.
A professor of medicine at Yale School of Medicine, Dr. Burtness’ research lab is actively studying new cures for head and neck cancers. “We want to help improve these patients’ quality of life,” she says.

Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several leadership positions in the field including President Emeritus of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the National Cancer Institute, and member of the FDA’s Oncology Drug Advisory Committee. She also currently serves as the Editor-in-Chief for JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and, in 2021, she was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity.

Oncologist Patricia LoRusso, DO, associate director of innovative medicine at Yale Medicine, has expertise in testing new treatments on patient volunteers who have advanced stages of cancer. Her passion is bringing research breakthroughs into the clinic to help patients with different types and stages of cancer.
The clinical trials at Yale Cancer Center offer access to experimental drugs that are sometimes a patient’s last and best hope, says Dr. LoRusso. Therapies that prove successful can advance through the U.S. Food and Drug Administration approval process. “Many of the drugs tested here will help generations of cancer patients,” says Dr. LoRusso. In her career, 14 cancer drugs she has performed clinical trials on, which she refers to as her “children,” have gone on to gain FDA approval.
Dr. LoRusso leads the Phase I clinical trials infusion center at Smilow Cancer Hospital at Yale New Haven. She infuses the center with a warm, team-focused approach that puts patients at the center of care. “We’re improving patients’ lives in Connecticut and beyond,” says Dr. LoRusso.

Michael Cecchini, MD, is a medical oncologist who specializes in gastrointestinal cancers, including (but not limited to) colorectal, bile duct, pancreas, esophageal, and stomach cancers. He often cares for patients with advanced gastrointestinal cancers and is an investigator in multiple research trials to help them get treatments that are not always available elsewhere.
“Taking care of patients and spending the time to get to know them is the best part of my job,” Dr. Cecchini says. It helps to draw upon the diverse expertise of colleagues at Smilow and those in non-cancer specialties, he adds. “At Yale we have an excellent multidisciplinary team that will work hard to treat your cancer, manage your symptoms, and deliver the care you deserve as a patient.”
Dr. Cecchini was inspired to become a cancer specialist partly because he wanted to have opportunities to perform research to improve options for his patients. “Few specialties are so integrated with close patient relationships and translational research that can dramatically improve the lives of our patients and minimize side effects,” he says. His translational research includes clinical and lab projects to study DNA damage and the immune response, primarily for colorectal cancer. He is the recipient of a Young Investigator Award from the Conquer Cancer Foundation for research focused on metastatic gastric cancer and 2020 Scholar on the Yale Cancer Center K12 Calabresi Immuno-Oncology Training Program.